Formulation and evaluation of sustained release microbeads of Venlafaxine hydrochloride using various polymers.

B.Kasturibai, Ravi Meghawath, Dr.S.K.Umadevi, Sai vardhan, Jaya Singh, Manisha Lachoriya and G.Rajeswari.
Department of Pharmaceutics, St.Pauls College of Pharmacy, Affiliated to Osmania University, Hyderabad, India.

Corresponding Author: Dr.S.K.Umadevi
Department of Pharmaceutics, St.Pauls College of Pharmacy, Turkhyamjal (V), Hayathnagar (M), Ranga Reddy (Dt)-501510. Mob: (91)9940226447
E-mail: drumadeviphd@gmail.com

Abstract

The main aim of the study is to formulate Venlafaxine Hydrochloride loaded microbeads of sodium alginate using gelatin and pectin as release modifiers by Ionotropic Gellation Method. The microbeads were prepared by varying the concentration of sodium alginate, gelatin and pectin. The drug – polymer compatibility was studied by FTIR studies. No significant drug-polymer interaction were observed in FTIR studies. The prepared microbeads were evaluated mainly for the Sustained Release of the drug apart from the other tests like swelling ratio, particle size, drug entrapment, SEM, in vitro release study. Particle size distribution of the loaded formulations were measured by an optical microscope and particle size of optimized beads was determined by SEM. In vitro drug release profile of Venlafaxine Hydrochloride microbeads was examined in 0.1N Hydrochloric acid for first 2 hrs followed by pH 7.4 phosphate buffer for 8 hrs. The formulated beads had shown higher entrapment efficiency, drug loading, low particle size. The formulation F6 released Venlafaxine Hydrochloride for longer duration up to 10hrs.

Keywords: Venlafaxine Hydrochloride, Sodium alginate, Gelatin, Pectin, Microbeads, Ionotropic Gellation method, Sustained Release dosage form.

1. Introduction

Sustained release formulation (1-5)

Sustained release technology has emerged as an important new field in the development of pharmaceutical dosage form. Sustained release systems include any drug delivery system that achieves slow release of drug over an extended period of time. More precisely, sustained drug delivery can be defined as “Sustained drug action at a predetermined rate by maintaining a relatively constant, effective drug level in the body with concomitant minimization of undesirable effects”.
In sustained release dosage forms, a sufficient amount of drug is initially made available to the body to cause a desired pharmacological response. The remaining fraction is released periodically and is required to maintain the maximum initial pharmacological activity for some desirable period of time in excess of time expected from usual single dose. The onset of its pharmacologic action is often delayed and the duration of its therapeutic effects is sustained. A sustained release is facilitated through the consistent rejuvenation of drug molecules.

By the sustained release method therapeutically effective concentration can be achieved in the systemic circulation over an extended period of time, thus achieving better compliance of patients. The sustained plasma drug levels provided by sustained release products often eliminate the need for night dosing, which benefits not only the patients but the care given as well. The basic rationale of a sustained drug delivery system is to optimize the Biopharmaceutic, Pharmacokinetic and Pharmacodynamic properties of a drug in such a way that its unity is maximized through reduction in side effects and cure or control of condition in the shortest possible time by using smallest quantity of drug, administered by the most possible route.

Potential advantages and disadvantages of Sustained release drug delivery systems:

- Minimize or eliminate local side effects
- Minimize or eliminate systemic side effects
- Obtain less potentiating or reduction in drug activity in chronic use.
- Minimize drug accumulation with chronic dosing.

Sustained release drug delivery systems are also associated with some of the disadvantage like

- Dose dumping
- Reduced potential for dosage adjustment
- Increased first pass clearance
- Poor systemic availability in general

The various approaches or the novel drug delivery systems include: liposomes, microspheres, nanoparticles and microbeads.

**Microbeads (or) Microspheres**

"Microbeads or Microspheres are defined as solid spherical particles containing dispersed drug in either solution or micro-crystalline form".

Microbeads or Microspheres are small spherical particles, with diameters in the micrometer range (typically 1 μm to 1000 μm). Microspheres are sometimes referred to micro-particles and microbeads. Microspheres are characteristically free flowing powders consisting of proteins or synthetic polymers. The range of Techniques for the preparation of microspheres offers a Variety of opportunities to control aspects of drug administration and enhance the therapeutic efficacy of a given drug.

**Methods of preparation:**

Incorporation of solid, liquid or gases into one or more polymeric coatings can be done by microencapsulation technique. The different methods used for various microspheres preparation depends on particle size, route of administration, duration of drug release, method of cross linking, evaporation time and co-precipitation, etc. different preparation methods are:
2. Experimental Methodology

Preparation of standard curves of venlafaxine hydrochloride:
Concentration of venlafaxine hydrochloride in the solution was estimated by stable beam spectrophotometer at 229 nm. The standard curves were prepared in pH 1.2 HCl and pH 7.4 buffer (Phosphate) solutions.

Preparation of HCl buffer pH 1.2: 50 ml of the potassium chloride solution (0.2 M) was placed in a 200 ml volumetric flask and to it was added 85 ml of hydrochloric acid solution (0.2 M) and then distilled water was added to make the volume to 200 ml.

Preparation of buffer pH 7.4:
Dissolve 2.38 gm of disodium hydrogen phosphate, 0.19 gm of potassium dihydrogen phosphate and 8.0 gm of sodium chloride in sufficient water to produce 1000 ml.

Preparation of standard curve of venlafaxine HCl in 1.2 pH HCl buffer:
Accurately weighed 50 mg of venlafaxine HCl was dissolved in 50 ml of 0.1 N HCl (pH-1.2) (Conc. 1000 µg/mL). From this solution, 10 ml was pipetted out into 100 ml volumetric flask and volume was made up to with 0.1 N HCl (pH-1.2) (Conc. 100 µg/mL). Further 10 ml aliquot was taken from this solution (100 g/ml) and diluted to 100 ml with 0.1 N HCl (pH-1.2) to give 10 g/ml standard solution of drug.

Preparation of standard curve of Venlafaxine HCl in Phosphate Buffer pH 7.4.
100 mg of Venlafaxine hydrochloride was accurately weighed and dissolved in simulated tear fluid (phosphate buffer pH7.4) in a 100 ml volumetric flask then the volume was made up to 100 ml with phosphate buffer pH 7.4. This was primary stock solution, containing 1000 g/ml. From this primary stock solution 1 ml was pipetted out and transferred into a 100 ml volumetric flask and volume was made up to 100 ml with phosphate buffer pH 7.4, which contained the concentration of 10 g/ml (Second stock solution). From second stock solution aliquots equivalent to 2-10 g were pipette out into a series of 10 ml volumetric flask and volume was made up to 10 ml with phosphate buffer pH7.4. The absorbances of these solutions were measured against the phosphate buffer pH 7.4 as blank at 229 nm using UV-visible double beam spectrophotometer. Then a calibration curve was plotted taking concentration in g/ml on X-axis and absorbance on Y-axis.

Preparation of Alginate-Pectin Microbeads:
The drug loaded microbeads were prepared using optimized concentration of sodium alginate and Pectin as a coating polymer. To 50 ml of deionized water, Pectin was added and stirred with the electric stirrer to form mucilage. Then sodium alginate was added to form uniform dispersion. Weighed quantity of venlafaxine was added and homogenized for 5 min. The resulting dispersion was dropped through syringe with needle into 100 ml of 2% w/v aqueous calcium chloride solution and stirred at 100 rpm. After stirring for 1 hour, the formed beads were separated by filtration, washed with distilled water, dried at 50°C in an oven.

Preparation of Alginate–Gelatin Microbeads:
The drug loaded microbeads were prepared using optimized concentration of sodium alginate and gelatin as a coating polymer. To 50 ml of deionized water, gelatin was added and stirred with the electric stirrer to form mucilage. Then sodium alginate was added to form uniform dispersion. Weighed quantity of venlafaxine was added and homogenized for 5 min. The resulting dispersion was dropped through syringe with needle into 100 ml of 2% w/v aqueous calcium chloride solution and stirred at 100 rpm. After stirring for 1 hour, the formed beads were separated by filtration, washed with distilled water, dried at 50°C in an oven.

Formulation of Venlafaxine microbeads:
The venlafaxine microbeads were prepared by ionotropic gellation method. The microbeads were prepared using sodium alginate, pectin and gelatin as polymer and calcium chloride across linking agent. Total 6 formulations were finalized by incorporating concentrations of polymer and cross linking agent. The concentrations of drug along with other excipients were summarized in Table 1.
Table 1 Formulation of venlafaxine microbeads

| Formulation code | Venlafaxine (mg) | Sodium alginate (mg) | Pectin (mg) | Gelatine (mg) | CaCl₂ (%) | Glutaraldehyde (ml) |
|------------------|------------------|----------------------|-------------|---------------|-----------|---------------------|
| F1               | 250              | 0.25                 | -           | 0.25          | 2         | 1                   |
| F2               | 250              | 0.3125               | -           | 0.1875        | 2         | 1                   |
| F3               | 250              | 0.375                | -           | 0.125         | 2         | 1                   |
| F4               | 250              | 0.25                 | 0.25        | -             | 2         | 1                   |
| F5               | 250              | 0.3125               | 0.1875      | -             | 2         | 1                   |
| F6               | 250              | 0.375                | 0.125       | -             | 2         | 1                   |

Evaluation of Microbeads: \(^{10-15}\)

The prepared microbeads were evaluated by the following parameters

A) Particle size by optical microscopy.
B) Estimation of Percentage yield
C) Drug entrapment efficiency.
D) Scanning electron microscopic studies (SEM).
E) Swelling study.
F) In vitro drug release study.
G) Release kinetics.
H) Fourier transform infrared spectroscopy analysis.
I) Differential scanning calorimetric analysis.

A) Measurement of microbeads size by optical microscopy

Particle size of the prepared beads was determined using an optical microscope fitted with a stage and an ocular micrometer. Mean diameter was calculated by measuring diameter of 50mg dried microbeads of each formulations.

\[
\text{Entrapment efficiency} = \frac{\text{Estimated \% drug content in microspheres}}{\text{Theoretical \% drug content in microspheres}} \times 100
\]

D) Scanning electron microscopic studies (SEM)

The microbeads were mounted onto stubs using double sided adhesive tape and sputter coated with platinum using a sputter coater (Edward S 150, UK). The coated beads were observed under SEM (JEOL, JSM-6360, Kyoto, Japan) at the required magnification and at room temperature. The acceleration voltage used was 10 kV with the secondary electron image as a detector.

E) Swelling study

The dynamic swelling behavior of the microbeads was studied by the 50 mg of beads were incubated with 25 ml phosphate buffer solution pH 7.4 at 37°C. The beads were taken out at different time intervals and blotted carefully without pressing hard to remove the excess surface liquid. The swollen beads were weighed using the electronic microbalance. The percent water uptake (Q) at different time intervals was calculated.

F) In-vitro drug release study

In-vitro drug release study was carried out using a Dissolution Apparatus USP XIV-II. The dissolution medium was maintained at 37.0 ± 0.5 °C and 50 rpm speed. The dissolution medium consists of simulated intestinal fluid (pH 7.4 phosphate buffer) for 8 hours. At predetermined time 5ml aliquots were removed every 30mins and an equivalent amount of fresh dissolution medium was replaced. The amount of drug released was analysed at 229 nm spectrophotometrically.
G) Data analysis (curve fitting analysis)

To analyze the mechanism of the drug release kinetics of the dosage form, the data obtained were fitted to various kinetic equations of zero order, first order, Higuchi model and Korsmeyer - Peppas model and plotted as:

1. Cumulative percent drug released Vs time (Zero order plots)
2. Log cumulative percent drug remaining Vs time (First order plots)
3. Cumulative percent drug release Vs square root of time (Higuchi plots)
4. (percent drug release) 1/3 Vs time (Hixson crowell plot)
5. log cumulative percent drug release Vs log time (Korsmeyer-Peppas Plots)

Zero order kinetics:

Drug dissolution from dosage forms that do not disaggregate and release the drug slowly can be represented by the equation:

\[ Q_t - Q_0 = K_0 t \]

Where, \( Q_t \) is the amount of drug dissolved in time \( t \), \( Q_0 \) is the initial amount of drug in the solution (most times, \( Q_0 = 0 \))
\( K_0 \) is the zero order release constant expressed in units of concentration/time.

When the data is plotted as cumulative percent drug release versus time, if the plot is linear then the data obeys zero-order release kinetics, with slope equal to \( K_0 \).

First order kinetics:

The release of the drug which followed first order kinetics can be expressed by the equation:

\[ \log C = \log C_0 + K_1 / 2.303 \]

Where, \( C_0 \) is the initial concentration of drug, \( k \) is the first order rate constant \( t \) is the time.

The data obtained are plotted as log cumulative percentage of drug remaining vs. time which would yield a straight line with a slope of \(-K/2.303\).

Higuchi model:

The release of the drug which follows higuchi kinetics can be expressed by the equation:

\[ Q = K_H t^{1/2} \]

Where, \( K_H \) is the Higuchi dissolution constant \( Q \) is the amount of drug released in time \( t \)

The data obtained were plotted as cumulative percentage drug release versus square root of time.

Hixson crowell model:

Hixson crowell recognized that the particle regular area is proportional to the cube root of its volume. Hixson crowell equation is

\[ Wo^{1/3} - Wt^{1/3} = Ks \cdot t \]

Where, \( Wo = \) initial amount of drug in pharmaceutical dosage form \( W_t = \) remaining amount of drug in pharmaceutical dosage form at time \( t \) \( K_s = \) constant incorporating the surface volume relation
The data obtained are plotted as (percent drug release)1/3 verses time.

Korsmeyer-Peppas model:

To find out the mechanism of drug release, drug release data were fitted in Korsmeyer-Peppas equation which is expressed as:

\[ \frac{Q}{Q_0} = k t^n \]

Where, \( K_0 \) to \( K_2 \) were release rate constants \( Q/Q_0 \) was fraction of drug released at time \( t \), \( K \) was constant and \( n \) was diffusion constant that indicates general operating release mechanism. For Fickian (diffusion controlled) \( n \leq 0.5 \); for non Fickian (anomalous/zero order) release 'n' value is in between 0.5 to 1.0; for zero order release \( n=1.0 \); for super case transport II, \( n > 1.0 \).

To study the release kinetics, data obtained from in vitro drug release studies were plotted as log cumulative percentage drug release versus log time.

H) Fourier transform infrared spectroscopy (FTIR):

The samples were crushed with KBr to make pellets under hydraulic pressure of 600 kg, and then the FTIR spectra were recorded between 400 and 4000 cm\(^{-1}\).

I) Differential scanning calorimetric analysis (DSC):

The sample were heated from 0-3000C at heating rate of 100C/min under ARGON atmosphere using a micrometer (DSC Q20 V24.4 Build 116, TA Instruments, USA) and then thermograms were obtained.
3. Results and Discussion

Compatibility Studies

Drug lipid compatibility studies were carried out using FTIR spectral studies to establish the possible interaction in the formulations. The IR spectrum of Venlafaxine, sodium alginate, pectin & gelatine their physical mixture is shown in Fig 2-5.

The IR spectrum of venlafaxine drug was compared with IR spectrum of physical mixture of drug and polymer. The presence of all characteristic peaks of Venlafaxine in the IR spectrum of drug-polymer mixture confirmed the absence of any chemical interaction between the two drugs and polymer. The results were shown in table 2.

![Fig.2 FT IR spectrum of pure drug venlafaxine hydrochloride](image1)

![Fig.3 FT IR spectrum of pure drug venlafaxine hcl and sodium alginate](image2)
The FTIR spectrum of venlafaxine hydrochloride developed formulation revealed that major frequencies of functional groups of pure drug remain intact in the mixture of Venlafaxine HCL with different polymers. Hence there is no interaction between the drug and polymer used in the study.
Fig. 6 DSC Spectrum of venlafaxine hydrochloride, sodium alginate and pectin

Fig. 7 DSC Spectrum of Venlafaxine hydrochloride
Preparation of standard graphs

Standard graph of venlafaxine hydrochloride in 1.2 pH HCl

![Standard graph of Venlafaxine hydrochloride in pH 1.2 HCl buffer](image)

Fig.8 Standard curve of Venlafaxine hydrochloride in pH 1.2 HCl buffer

![Standard curve of Venlafaxine in phosphate buffer pH 7.4](image)

Fig.9 Standard curve of Venlafaxine in phosphate buffer pH 7.4

4.5 Particle size distribution

| Formulation | Particle size (µm) ±SD |
|-------------|------------------------|
| F1          | 172±1.6                |
| F2          | 185.4±0.8              |
| F3          | 197.6±1.2              |
| F4          | 160±1.4                |
| F5          | 182±1.0                |
| F6          | 210.4±1.8              |

Table 3 Particle size distribution
The size of the beads was determined using optical microscope and recorded in table 3. The average bead size was found to be in the range of 172±1.6 to 210.4±1.8µm. By increasing the sodium alginate concentrations in the beads, an increase in size of the beads was observed, also, by increasing the amount of drug, an increase in size of the beads was observed.

**Scanning Electron Microscopy:**

They were found to be smooth surfaced spherical intact beads in the optimized formula (F6).

![Fig.10 Scanning Electron Microscopic studies(F6)](image)

### 4.5 Percentage yield and drug entrapment efficiency (DEE) of venlafaxine microbeads

Percentage yield was found to be in range of 65% to 85%. Maximum percentage yield was found to be 85% for F6 formulation. Percentage yield increases with increase in concentration of the polymer added to formulation. The drug entrapment efficiency (DEE) of the prepared microbeads was studied, and the results are given in table 4. The drug entrapment efficiency was found to be in the range of 60-80%.

| Formulation | Percentage yield | Drug entrapment efficiency (%) |
|-------------|------------------|---------------------------------|
| F1          | 74.6±0.8         | 60±1.2                          |
| F2          | 57.3±1.0         | 68±1.4                          |
| F3          | 65.3±0.6         | 76±1.0                          |
| F4          | 77.6±0.8         | 69±0.6                          |
| F5          | 74.6±1.6         | 73±0.8                          |
| F6          | 85±1.2           | 80±1.4                          |

**Table 4 Percentage Yield and Drug Entrapment Efficiency (DEE) of venlafaxine Hydrochloride beads for various combinations. (F1-F6)**

The swelling study of microbeads in phosphate buffer pH 7.4

The swelling study of the prepared microbeads was carried out in phosphate buffer pH 7.4 and it was expressed as the ratio of initial weight of beads to the final weight of swollen beads as a function of time. The swelling of microbeads depends upon the concentrations of sodium alginate in the beads which increased with an increasing amount of sodium alginate in the beads.
Table 5 Swelling Index of F1 to F6 in Phosphate buffer pH 7.4

| TIME (Hrs) | F1 | F2 | F3 | F4 | F5 | F6 |
|------------|----|----|----|----|----|----|
| 30         | 31 | 43 | 57 | 31 | 45 | 66 |
| 1          | 37 | 47 | 60 | 32 | 49 | 69 |
| 1.5        | 43 | 49 | 63 | 49 | 55 | 72 |
| 2          | 47 | 55 | 70 | 52 | 60 | 80 |
| 2.5        | 55 | 60 | 82 | 58 | 72 | 85 |
| 3          | 57 | 70 | 90 | 60 | 81 | 97 |

Table 6 *In vitro* cumulative %drug release data of Venlafaxine hydrochloride and gelatin microbeads

| TIME (Hrs) | F1(%) | F2(%) | F3(%) |
|------------|-------|-------|-------|
| 30         | 2±0.66| 2±0.04| 6±1.02|
| 1          | 5±0.64| 5±1.24| 13±1.25|
| 2          | 10±1.2| 11±0.92| 23±0.96|
| 3          | 26±1.4| 29±0.98| 39±0.92|
| 4          | 30±0.82| 37±1.0| 49±1.32|
| 5          | 31±0.96| 42±0.42| 52±1.42|
| 6          | 33±0.12| 46±0.98| 56±1.22|
| 7          | 34±0.84| 48±0.46| 61±1.42|
| 8          | 35±0.96| 50±1.80| 67±0.86|
| 9          | 36±1.0| 51±1.42| 68±1.64|
| 10         | 36±0.90| 53±0.98| 73±1.02|

**Fig.11 In vitro drug release profile of venlafaxine hydrochloride gelatin beads**
### Table 7 *In vitro* cumulative % drug release data of Venlafaxine hydrochloride pectin microbeads

| TIME (Hrs) | F4(%)  | F5(%)  | F6(%)  |
|------------|--------|--------|--------|
| 30         | 6±1.2  | 6±1.4  | 23±0.82|
| 1          | 13±1.0 | 13±0.92| 37±0.96|
| 2          | 25±0.8 | 25±0.84| 41±0.48|
| 3          | 28±0.6 | 39±0.68| 56±0.86|
| 4          | 39±0.6 | 49±0.72| 63±0.94|
| 5          | 49±1.0 | 52±0.93| 69±1.4 |
| 6          | 52±0.9 | 56±0.58| 77±1.6 |
| 7          | 56±0.8 | 61±0.74| 86±1.2 |
| 8          | 58±0.4 | 67±0.92| 89±0.84|
| 9          | 60±0.8 | 68±1.02| 90±0.92|
| 10         | 61±1.0 | 75±1.04| 92±0.94|

**Fig.12 In vitro drug release profile of Venlafaxine hydrochloride pectin beads**

The *in-vitro* drug release study was performed using dissolution test apparatus in phosphate buffer pH 7.4 and 0.1N HCl.

The *in-vitro* drug release studies of gelatine microbeads (F1 to F3) the cumulative percentage drug release was observed in the range of 36±0.9% to 73±1.02%. The *in-vitro* drug release studies of pectin microbeads (F4 to F6) the cumulative percentage drug release was observed in the range of 61±1.0% to 92±0.94%. Compared to the gelatin microbeads pectin microbeads shows more sustained release. The best formulation was observed as F6.

#### 4.8 Data analysis (curve fitting analysis):

For analyzing the mechanism of the drug release kinetics of the dosage form, the data obtained were fitted to various kinetic equations of zero order, first order, Higuchi model, hixson-crowell and Korsmeyer-Peppas model. The regression coefficient is calculated. Graphs of kinetic models were plotted with suitable data which was summarized in table no 4.10.

For first order release kinetics, for Higuchi release kinetics, for Hixson-crowell and for Korsmeyer-Peppas release kinetics.
Table 8 Kinetic data of optimized formulation F6

| TIME | ROOT (T) | LOG (T) | CUMUATIVE %DR | LOG %DR | LOG %REMAIN | (%DR)^1/3 |
|------|----------|---------|---------------|---------|-------------|-----------|
| 0    | 0        | -       | 0             | -       | 2.000       | 0.000     |
| 0.5  | 0.707    | 0.301   | 23            | 1.362   | 1.886       | 0.387     |
| 1    | 1.000    | 0.000   | 37            | 1.568   | 1.799       | 0.663     |
| 2    | 1.414    | 0.301   | 41            | 1.613   | 1.771       | 0.749     |
| 3    | 1.732    | 0.477   | 56            | 1.748   | 1.643       | 1.111     |
| 4    | 2.000    | 0.602   | 63            | 1.799   | 1.568       | 1.309     |
| 5    | 2.236    | 0.699   | 69            | 1.839   | 1.491       | 1.500     |
| 6    | 2.449    | 0.778   | 77            | 1.886   | 1.362       | 1.798     |
| 7    | 2.846    | 0.845   | 86            | 1.934   | 1.146       | 2.231     |
| 8    | 2.828    | 0.903   | 89            | 1.949   | 1.041       | 2.418     |
| 9    | 3.000    | 0.954   | 90            | 1.954   | 1.000       | 2.487     |
| 10   | 3.162    | 1.000   | 92            | 1.964   | 0.903       | 2.487     |

Fig.13 zero order release kinetics of optimized formulation F6

Fig.14 first order release kinetics of optimized formulation F6
Fig. 15 Higuchi release kinetics of optimized formulation F6

Fig. 16 Hixson Crowell release kinetics of optimized formulation F6

Fig. 17 Korsemeyer Peppas release kinetics of optimized formulation F6
Table 9  $r^2$ values of different kinetic models

| Formulation | Zero order | First order | Higuchi model | Korsemeyer peppas model | Hixson crowell model |
|-------------|------------|-------------|---------------|------------------------|---------------------|
|             | $r^2$      | $N$         | $r^2$         | $N$                    | $r^2$               |
| F1          | 0.827      | 0.850       | 0.911         | 0.985                  | 1.195               |
| F2          | 0.898      | 0.934       | 0.935         | 0.985                  | 1.332               |
| F3          | 0.931      | 0.985       | 0.975         | 0.985                  | 0.923               |
| F4          | 0.923      | 0.964       | 0.973         | 0.985                  | 0.855               |
| F5          | 0.935      | 0.987       | 0.978         | 0.985                  | 0.921               |
| F6          | 0.897      | 0.986       | 0.980         | 0.985                  | 0.463               |

Where, $r^2$ = regression coefficient  
$n$ = slope

Based on the mathematical data revealed from kinetic models, it was concluded that the release data was best fitted with Higuchi model. Higuchi equation explains the diffusion controlled release mechanism, the diffusion exponent ‘n’ values were found to be less than 0.5 indicating Fickian diffusion.

**Conclusion**

Sodium alginate- pectin based microbeads comprising of venlafaxine hydrochloride can be successfully formulated by ionotropic gelation method. The preformulation studies like melting point, solubility and UV analysis of venlafaxine hydrochloride complied with IP standard. Compatibility studies are carried out by FT-IR spectroscopic studies revealed that there is no significant interaction between drug and polymer. Polymer- drug ratio showed an influence on the particle size, swelling index, cumulative % drug release and drug entrapment efficiency. Among the six batches F6 showed better drug release of 92±0.94% for 10hrs which is matching the objective of the study. Therefore, it is concluded that the venlafaxine hydrochloride microbeads prepared with sodium alginate and pectin in the ratio of 3:1 is a successful pharmaceutical dosage form for providing sustained release drug delivery of the drug and improving bioavailability.

**Acknowledgments**

The authors are thankful to Mr. K. Sudhir, the honourable Chairman and Mr. T. Raghava Reddy, honourable secretary, St. Pauls group of colleges, for providing all infrastructure and facilities to carry out the research in our college.

**References**

1. Yie w. chein; Novel drug delivery systems second edition, 139-196
2. Martin Alfred, Phsical Pharmacy, 4th edn, B.I. Waverly Pvt, Ltd, Newdelhi;1991; 760..
3. S.P.Vyas and R.K.Khar ; Targeted and controlled drug delivery novel carrier system page no 17-457
4. Indian Pharmacopoeia 2007, (1) 142-143.
5 Simon Benita; microencapsulation, methods and industrial Applications, second edition, 183-205.
6. Nicholas G.L., Sustained release dosage forms, Leon Lachmann, The Theory and Practice of Industrial Pharmacy,3rd edition, Varghese Publishing house, Mumbai; Page No:230.
7.Santanu Chakraborty. Fabrication and Characterization of AlginocarbopolMicroparticulate System of Aceclofenac for Oral Sustained Drug Delivery. International Journal of Pharmaceutical Sciences Review and Research .4(2); 2010:192-199.
8. Shabeena aqdas et al. Formulation and in vitro evaluation of stomach specific floating microspheres of Simvastatin. Int.Journal of pharmacy, 2014,5(11).
9. D. NagasamyVenkatesh, et al. Development and invtro evaluation of sodium alginate microbeads of Carvedilol.International journal of pharma research.2009:53-56.
10. J.Saivardhan et al. Formulation and evaluation of Sustained release microspheres of Pregabalin for the effective treatment of epilepsy. Int.J. Curr. Chem. Pharma. Sci 1(10);2014:120-130
11. Manjanna K.M, Shivakumar.B, Pramod kumarT.M. Diclofenac sodium microbeads for oral sustained drug delivery. International journal of Pharmtech Research .1(2); 2009:317-327.
12. Sarat Chandra Prasad.M, S.Brito Raj, M.Ajay, B.NagendraBabu, N.Audinarayana, K.Bhaskar Reddy et al. Formulation and evaluation of lamivudine enclosed alginate microbeads. Der Pharmacia Lettre. 3(6);2011:294-304.
13. Chanukya Kumar G et al. Formulation and evaluation of Norfloxacin beads. International Journal of Institutional Pharmacy and Life Sciences .1(1); 2011:328-339.
14. Jakir Ahmed Chowdhury, Sheikh Tasnim Jahan, Md. Masud Morshed, Jewel Mallick, Aninda Kumar Nath, Md Zia Uddin et al. Development and Evaluation of Diclofenac Sodium Loaded Alginate Cross-Linking Beads. Bangladesh Pharmaceutical Journal. 14(1); 2011:41-48.

15. Sanchita Mandal, S. Senthil Kumar, Balakrishnam Krishnamoorthy, Sanat Kumar Basu. Development and evaluation of calcium alginate beads prepared by sequential and simultaneous methods. Brazilian Journal of Pharmaceutical Sciences. 46(4); 2010: 785-793.

How to cite this article: B.Kasturibai, Ravi Meghawath, Dr.S.K.Umadevi, Sai vardhan, Jaya Singh, Manisha Lachoriya and G.Rajeswari. (2016). Formulation and evaluation of sustained release microbeads of Venlafaxine hydrochloride using various polymers. Int. J. Curr. Res. Chem. Pharm. Sci. 3(12): 44-59. DOI: http://dx.doi.org/10.22192/ijcrcps.2016.03.12.008